Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.
de Koster EJ, van Engen-van Grunsven ACH, Bussink J, Frielink C, de Geus-Oei LF, Kusters B, Peters H, Oyen WJG, Vriens D; EFFECTS trial study group. de Koster EJ, et al. Mol Imaging Biol. 2023 Jun;25(3):483-494. doi: 10.1007/s11307-022-01776-4. Epub 2022 Oct 17. Mol Imaging Biol. 2023. PMID: 36253663 Free PMC article. Clinical Trial.
Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings.
Collarino A, de Koster EJ, Valdés Olmos RA, de Geus-Oei LF, Pereira Arias-Bouda LM. Collarino A, et al. Among authors: de koster ej, de geus oei lf. Clin Breast Cancer. 2018 Feb;18(1):9-18. doi: 10.1016/j.clbc.2017.06.008. Epub 2017 Jun 29. Clin Breast Cancer. 2018. PMID: 28728876
[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial.
de Koster EJ, de Geus-Oei LF, Brouwers AH, van Dam EWCM, Dijkhorst-Oei LT, van Engen-van Grunsven ACH, van den Hout WB, Klooker TK, Netea-Maier RT, Snel M, Oyen WJG, Vriens D; EfFECTS trial study group. de Koster EJ, et al. Among authors: de geus oei lf. Eur J Nucl Med Mol Imaging. 2022 May;49(6):1970-1984. doi: 10.1007/s00259-021-05627-2. Epub 2022 Jan 4. Eur J Nucl Med Mol Imaging. 2022. PMID: 34981165 Free PMC article. Clinical Trial.
Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules.
de Koster EJ, Noortman WA, Mostert JM, Booij J, Brouwer CB, de Keizer B, de Klerk JMH, Oyen WJG, van Velden FHP, de Geus-Oei LF, Vriens D; EfFECTS trial study group. de Koster EJ, et al. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2174-2188. doi: 10.1007/s00259-022-05712-0. Epub 2022 Feb 9. Eur J Nucl Med Mol Imaging. 2022. PMID: 35138444 Free PMC article. Clinical Trial.
FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.
de Koster EJ, Vriens D, van Aken MO, Dijkhorst-Oei LT, Oyen WJG, Peeters RP, Schepers A, de Geus-Oei LF, van den Hout WB; EfFECTS trial study group. de Koster EJ, et al. Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3452-3469. doi: 10.1007/s00259-022-05794-w. Epub 2022 Apr 18. Eur J Nucl Med Mol Imaging. 2022. PMID: 35435497 Free PMC article. Clinical Trial.
In reaction to: Thuillier P, Benisvy D, Ansquer C, Corvilain B, Mirallie E, Taieb D, et al. Section 5: What is the role of functional imaging and isotopic treatment? Ann Endocrinol (Paris) 2022;83:401-6. https://doi.org/10.1016/j.ando.2022.10.008.
de Koster EJ, de Geus-Oei LF, Oyen WJG, Vriens D. de Koster EJ, et al. Ann Endocrinol (Paris). 2023 Apr;84(2):325-326. doi: 10.1016/j.ando.2022.12.002. Epub 2022 Dec 21. Ann Endocrinol (Paris). 2023. PMID: 36641242 No abstract available.
16 results